Molecular subtyping classified the cases into luminal HER2/neu (25%), luminal B (23%), triple-negative (19%), HER2/neu enriched (16%), and luminal A (17%), highlighting the heterogeneity of DCIS. Here, ERBB2 is linked to ductal breast carcinoma in situ.